About: Imagabalin

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.

thumbnail
Property Value
dbo:abstract
  • Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development. (en)
  • イマガバリン(Imagabalin)は、電圧依存性カルシウムチャネルのα2δサブユニットのリガンドとして作用する。α2δ2サブユニットと比べてα2δ1サブユニットに対する選択性がある。ファイザーによって医薬品として開発されていたには、抗不安薬、鎮痛剤、睡眠薬、抗てんかん薬の作用が非臨床試験で示されていた。現在は、全般性不安障害の治療についての、第三相臨床試験が実施されている。 (ja)
dbo:casNumber
  • 610300-00-0 (hydrochloride)
  • 610300-07-7
dbo:fdaUniiCode
  • NDG6931B7H
dbo:kegg
  • D09627
dbo:pubchem
  • 10236037
dbo:thumbnail
dbo:wikiPageID
  • 35589181 (xsd:integer)
dbo:wikiPageLength
  • 4160 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1011406047 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:c
  • 9 (xsd:integer)
dbp:casNumber
  • 610300 (xsd:integer)
dbp:casSupplemental
  • 610300 (xsd:integer)
dbp:chemspiderid
  • 8411525 (xsd:integer)
dbp:h
  • 19 (xsd:integer)
dbp:iupacName
  • -3 (xsd:integer)
dbp:kegg
  • D09627 (en)
dbp:n
  • 1 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:pubchem
  • 10236037 (xsd:integer)
dbp:smiles
  • O=CC[C@@H]C[C@@H]C (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • JXEHXYFSIOYTAH-SFYZADRCSA-N (en)
dbp:synonyms
  • PD-0332334; PD-332,334 (en)
dbp:unii
  • NDG6931B7H (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development. (en)
  • イマガバリン(Imagabalin)は、電圧依存性カルシウムチャネルのα2δサブユニットのリガンドとして作用する。α2δ2サブユニットと比べてα2δ1サブユニットに対する選択性がある。ファイザーによって医薬品として開発されていたには、抗不安薬、鎮痛剤、睡眠薬、抗てんかん薬の作用が非臨床試験で示されていた。現在は、全般性不安障害の治療についての、第三相臨床試験が実施されている。 (ja)
rdfs:label
  • Imagabalin (en)
  • イマガバリン (ja)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License